Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).

Awards include options on 18,025 shares at $24.02 and 3,900 restricted stock units with multi-year vesting.

Argus Jul 6 session 5 alerts

-3.97% close to close 0.4x rel. volume Open Argus

Details

Market move: GLUE -3.97% in the Jul 6 session. inducement equity awards

$2.05B Mkt Cap at Peak Alert

On Jul 6, the first trading day after this news, GLUE closed 3.97% below the previous close. Our momentum scanner recorded 5 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 6 session.

Key Figures

Inducement stock options: 18,025 shares Option exercise price: $24.02 per share Inducement RSUs: 3,900 shares +3 more

Inducement stock options

18,025 shares

Non-qualified options granted to three new non-executive employees

Option exercise price

$24.02 per share

Exercise price equal to Nasdaq closing price on July 1, 2026

Inducement RSUs

3,900 shares

Restricted stock units granted in aggregate to new employees

Initial option vesting

25%

Vests on first anniversary of Grant Date, then monthly thereafter

Subsequent option vesting

36 monthly installments

Remaining 75% of options vest monthly after first anniversary

RSU vesting schedule

25% annually over 4 years

RSUs vest on each of first four Grant Date anniversaries

Historical Context

5 past events · Latest: Jun 02

5 events

1. Jun 02

   Inducement grants

   24h Move

   -0.8%

   Inducement stock options and RSUs granted to new non-executive employees.

2. May 20

   Conference participation

   24h Move

   +7.5%

   Upcoming participation in TD Cowen oncology and Jefferies healthcare investor conferences.

3. May 07

   1Q26 earnings report

   24h Move

   -2.8%

   Q1 2026 financials and clinical updates including MRT-8102 and MRT-2359 data.

4. May 05

   Inducement grants

   24h Move

   +5.4%

   Inducement equity awards for four new non-executive employees under 2026 plan.

5. Apr 20

   Preclinical data

   24h Move

   +0.1%

   AACR presentation on CCNE1-directed degrader MRT-55811 preclinical tumor regression data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4), inducement plan

4 terms

non-qualified stock options financial

"non-qualified stock options to purchase 18,025 shares of Monte Rosa"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units for an aggregate of 3,900 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"pursuant to the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan."

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to three newly hired non-executive employees as a material inducement to commencing their employment with the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 18,025 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $24.02 as reported by Nasdaq on July 1, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 3,900 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of stockholder-approved equity incentive plans and are pursuant to the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity grants did Monte Rosa (GLUE) announce on July 2, 2026?

Monte Rosa announced stock options and restricted stock units for three new employees. According to Monte Rosa, the grants cover options on 18,025 shares and 3,900 RSUs, serving as material inducements for the employees to commence employment with the company.

What is the exercise price and vesting schedule of Monte Rosa GLUE inducement stock options?

The inducement stock options have a $24.02 exercise price per share. According to Monte Rosa, 25% of options vest on the first anniversary of the July 1 Grant Date, with the remainder vesting in 36 equal monthly installments, subject to continued employment.

How do Monte Rosa (GLUE) inducement restricted stock units vest for new employees?

The inducement restricted stock units vest over four years. According to Monte Rosa, 25% of the 3,900 RSUs vest on each of the first four anniversaries of the Grant Date, contingent on the employee’s continued service with the company at each vesting date.

Were Monte Rosa GLUE inducement awards granted under a stockholder-approved equity plan?

The inducement awards were granted outside stockholder-approved equity incentive plans. According to Monte Rosa, they were issued under the 2026 Inducement Plan and approved by the independent compensation committee as material inducements in line with Nasdaq Listing Rule 5635(c)(4).

Why does Monte Rosa use Nasdaq Listing Rule 5635(c)(4) for GLUE inducement grants?

Monte Rosa uses Nasdaq Listing Rule 5635(c)(4) to grant equity as hiring inducements. According to Monte Rosa, these awards are material incentives for new employees and are approved by an independent compensation committee, allowing grants outside stockholder-approved equity plans.